Results 111 to 120 of about 98,010,213 (261)

Comparison of Four SARS-CoV-2 Neutralization Assays

open access: yesVaccines, 2020
Neutralizing antibodies are a major correlate of protection for many viruses including the novel coronavirus SARS-CoV-2. Thus, vaccine candidates should potently induce neutralizing antibodies to render effective protection from infection.
Lydia Riepler   +6 more
doaj   +1 more source

Antibodies, epicenter of SARS-CoV-2 immunology [PDF]

open access: yesCell Death & Differentiation, 2021
Pecetta, Simone   +8 more
openaire   +2 more sources

Prevalence of anti-SARS-CoV-2 antibodies in the general population in Belgium: First results of the SalivaHIS study

open access: yes, 2021
Key findings In the beginning of July 2021 78.1% of the community dwelling population aged 18 years and above had developed anti-SARS-CoV-2 antibodies.
V. Leclercq   +3 more
core  

Table_1_Growth, Antigenicity, and Immunogenicity of SARS-CoV-2 Spike Variants Revealed by a Live rVSV-SARS-CoV-2 Virus.XLSX

open access: yes, 2022
SARS-CoV-2 is an emerging coronavirus threatening human health and the economy worldwide. As an RNA virus, variants emerge during the pandemic and potentially influence the efficacy of the anti-viral drugs and vaccines.
Hongyue Li (220214)   +9 more
core   +1 more source

Intelligent Programmable Membrane Nanosponge for Early Virus Blocking

open access: yesAdvanced Science, EarlyView.
A smart programmable nanosponge (ACNPs) displays high‐density viral receptors on its membrane and encapsulates fusion inhibitors to capture virions at the infection source through competitive binding and blocks their entry through protease inhibition for ultra‐early cascade interception. This modular, mucus‐penetrating platform shifts antiviral defence
Ze Chen   +17 more
wiley   +1 more source

The dynamics of antibodies to SARS-CoV-2 in a case of SARS-CoV-2 infection [PDF]

open access: yesInternational Journal of Infectious Diseases, 2020
Xia, Yong   +5 more
openaire   +3 more sources

Characterizing SARS-CoV-2 antibodies

open access: yesChemical & Engineering News, 2020
ntibody therapeutics will be a key part of the fight against COVID-19, but some do a better job of neutralizing SARS-CoV-2 than others These antibodies stop infection by blocking the virus from entering cells Researchers have now used structural biology techniques and binding assays to show four basic modes by which different neutralizing antibodies ...
openaire   +1 more source

Table_2_Growth, Antigenicity, and Immunogenicity of SARS-CoV-2 Spike Variants Revealed by a Live rVSV-SARS-CoV-2 Virus.XLSX

open access: yes, 2022
SARS-CoV-2 is an emerging coronavirus threatening human health and the economy worldwide. As an RNA virus, variants emerge during the pandemic and potentially influence the efficacy of the anti-viral drugs and vaccines.
Hongyue Li (220214)   +9 more
core   +1 more source

Lyssavirus Nucleoprotein Induces GPAT4‐Mediated CYB5R1 Depalmitoylation to Suppress Ferroptosis and Promote Viral Replication

open access: yesAdvanced Science, EarlyView.
Lipid metabolism plays a vital role in viral infections. Here, we reveal that the lyssavirus N protein regulates GPAT4 to induce lipid droplet biogenesis, restricting CYB5R1 palmitoylation and reducing ferroptosis susceptibility to ultimately promote viral replication.
Jianqing Zhao   +6 more
wiley   +1 more source

Site‐Specific Protein Bioconjugation Through Cellular Incorporation of Noncanonical Amino Acids

open access: yesAngewandte Chemie, EarlyView.
Genetic code expansion (GCE) enables site‐specific installation of noncanonical amino acids containing bioorthogonal conjugation handles, allowing precise, homogeneous protein modification. This review examines the principles of orthogonal translation, surveys the chemistries available for chemoselective labeling, and highlights emerging multi‐site ...
Rahul Sarkar   +2 more
wiley   +2 more sources

Home - About - Disclaimer - Privacy